Public Employees Retirement System of Ohio bought a new position in shares of Ralliant Corporation (NYSE:RAL – Free Report) during the 2nd quarter, HoldingsChannel reports. The firm bought 33,603 shares of the company’s stock, valued at approximately $2,474,000.
A number of other large investors have also recently made changes to their positions in RAL. BlackRock Inc. bought a new stake in shares of Ralliant during the 2nd quarter valued at $1,039,481,000. Viking Global Investors LP purchased a new position in Ralliant during the 2nd quarter valued at about $257,200,000. State Street Corp bought a new stake in shares of Ralliant during the second quarter valued at about $213,096,000. Millennium Management LLC lifted its holdings in shares of Ralliant by 172.4% in the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after buying an additional 3,147,660 shares in the last quarter. Finally, Flossbach Von Storch SE bought a new position in shares of Ralliant in the second quarter valued at approximately $222,460,000.
Ralliant Stock Up 1.1%
Shares of NYSE:RAL opened at $63.46 on Friday. The firm has a market capitalization of $7.02 billion, a PE ratio of -5.85, a price-to-earnings-growth ratio of 2.36 and a beta of 1.54. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41. The firm has a fifty day moving average of $67.52 and a 200 day moving average of $57.10.
Ralliant Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be given a $0.05 dividend. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s payout ratio is presently -1.84%.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on RAL shares. Morgan Stanley upped their target price on shares of Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a report on Tuesday, June 23rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a report on Friday, July 31st. Truist Financial reiterated a “buy” rating and issued a $82.00 price objective (up from $68.00) on shares of Ralliant in a research report on Friday, July 31st. Barclays lifted their price objective on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen cut Ralliant from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 30th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.70.
Get Our Latest Research Report on Ralliant
Insider Activity at Ralliant
In other news, SVP Karen M. Bick sold 6,062 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the sale, the senior vice president directly owned 31,668 shares in the company, valued at approximately $2,280,096. The trade was a 16.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $71.79, for a total transaction of $928,675.44. Following the completion of the sale, the chief executive officer owned 251,967 shares of the company’s stock, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is owned by corporate insiders.
Ralliant Profile
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Featured Articles
- Five stocks we like better than Ralliant
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL – Free Report).
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
